<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148106">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059187</url>
  </required_header>
  <id_info>
    <org_study_id>1293-006</org_study_id>
    <secondary_id>2012-003478-19</secondary_id>
    <nct_id>NCT02059187</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus™ participants
      with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Confrmed Anti-Insulin Antibodies up to Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Participant Hemoglobin A1C Level at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Body Weight at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Hypoglycemia Up to Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE) Up to Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Daily Insulin Dose (Units) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Insulin Dose Per Body Weight (Units/kg) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant 7-Point Self-Monitored Blood Glucose (SMBG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hemoglobin A1C &lt;7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hemoglobin A1C &lt;6.5% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-1293</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1293 administered subcutaneously once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lantus™ administered subcutaneously once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1293</intervention_name>
    <description>MK-1293 administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.</description>
    <arm_group_label>MK-1293</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus™</intervention_name>
    <description>Lantus™ administered subcutaneously. Dosing will be initiated based on the participant's prior insulin dosing, and may be modified at the investigator's discretion to meet the individual participant's needs.</description>
    <arm_group_label>Lantus™</arm_group_label>
    <other_name>Insulin glargine [rDNA origin]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM) as defined by the American Diabetes
             Association (ADA) or the European Association for the Study of Diabetes (EASD)

          -  hemoglobin A1C of ≤11.0% and requires insulin for glycemic control

          -  Body mass index (BMI) &lt;45 kg/m^2

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis, or has type 1
             diabetes confirmed with a C-peptide &lt;0.7 ng/mL (0.23 nmol/L)

          -  One or more severe hypoglycemic episodes associated with hypoglycemic seizures, comas
             or unconsciousness within the past 6 months

          -  History of intolerance or hypersensitivity to Lantus™ or contraindication to Lantus™
             or one of its excipients based on the label of the country of the investigational
             site

          -  On a weight loss program within the last 8 weeks

          -  Received injectable incretin-based therapy (e.g., Victoza™, Byetta™) within

        the prior 8 weeks

          -  Bariatric surgery within 12 months prior to signing the informed consent

          -  Likely to require treatment for ≥2 consecutive weeks or repeated courses of

        corticosteroids

          -  Undergone a surgical procedure within 4 weeks prior to signing informed

        consent or has planned major surgery during the study

          -  New or worsening signs or symptoms of coronary heart disease or congestive heart
             failure within the last 3 months

          -  Presence of any of the following during the last 3 months: acute coronary syndrome,
             coronary artery intervention, and/or stroke or transient ischemic neurological
             disorder

          -  Severe peripheral vascular disease

          -  Systolic blood pressure ≥ 160 mm Hg or a diastolic ≥95 mm Hg and blood pressure is
             not considered likely to be under these limits with an adjustment in antihypertensive
             medication

          -  Chronic myopathy or a progressive neurological or neuromuscular disorder

          -  Active nephropathy

          -  History of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
             gallbladder disease

          -  Human immunodeficiency virus (HIV)

          -  Clinically important hematological disorder (such as aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  History of malignancy ≤5 years prior to signing informed consent, except for
             adequately treated basal cell or squamous cell skin cancer, or in situ cervical
             cancer

          -  History of melanoma, leukemia, lymphoma, or renal cell carcinoma

          -  Hyperthyroidism

          -  On a stable dose of thyroid hormone replacement therapy for &lt;6 weeks

          -  Uses recreational or illicit drugs or has had a recent history (within the last year)
             of drug or alcohol abuse or dependence

          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs

        during the study, including 14 days following the last dose of study drug

          -  Donated blood products or has had phlebotomy of &gt;300 mL within 8 weeks of signing
             informed consent, or intends to donate blood products within the projected duration
             of the study

          -  Poor mental function or any other reason to expect that the participant may

        have difficulty in complying with the requirements of the study

          -  Clinically significant ECG abnormality which exposes the participant to risk by
             enrolling in the study

          -  Positive urine pregnancy test

          -  Participant is a night shift worker which causes difficulty complying with the
             overnight fast requirement and has potential for confounding the 7-point SMBG
             analysis

          -  Participant, as assessed by the investigator, is not appropriate for or does not
             agree to target a fasting glucose of 70-100 mg/dL [3.9 -5.6 mmol/L]

          -  Has used a formulation of glargine insulin other than Lantus™
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2100)</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2110)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2109)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2107)</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2101)</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2113)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2105)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2108)</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2102)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2106)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2104)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Jankelowitz</last_name>
      <phone>61 2 8988 8246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Carvajal</last_name>
      <phone>57 1219109011090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (New Zealand) Ltd.,</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Jankelowitz</last_name>
      <phone>61 2 8988 8246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Colombia</country>
    <country>New Zealand</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
